We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Early Biomarker Identified for Future Allergies in Children

By LabMedica International staff writers
Posted on 25 Jul 2011
A marker of inflammatory cells found in the urine of newborn babies was linked to a higher risk of allergic sensitization, nasal eosinophilia and eczema at six years.

Biomarkers predicting development of atopic disease before the onset of symptoms are needed for targeted prevention as well as individualized intervention and treatment. More...


Scientists at the University of Copenhagen, (Denmark), measured the level of urinary eosinophil protein-X (u-EPX), and several other markers of inflammation, in 369 healthy month-old infants. The children were enrolled in a birth cohort study of symptom-free month-old children born to asthmatic mothers. Their blood eosinophil count was also taken at intervals. Nasal eosinophilia was investigated by nasal scraping in the child's sixth year of life, and allergic rhinitis was diagnosed by age six based on interviews of parents and the child's history of symptoms. Asthma-like symptoms and diagnoses of asthma and eczema were also noted.

In the first year of life, 4% of the children developed asthma-like symptoms and 27% were diagnosed with eczema. Another 17% went on to develop asthma-like symptoms and 15% developed eczema by age six. The investigators analyzed the data for associations between infant levels of u-EPX and future symptoms and diagnoses, and found that elevated u-EPX at one month was associated with 49% increase in risk of allergic sensitization, an association that was statistically significant for both food and aeroallergens.

High u-EPX was also associated with a three-fold risk of developing nasal eosinophilia, indicating allergic inflammation of the upper airways. Finally, infants whose u-EPX was in the top quartile had a 40% greater risk for developing eczema by the age of six than those in the lower three quartiles. The u-EPX concentration was determined by a commercial double-antibody radioimmunoassay.

Hans Bisgaard, MD, DMSci, professor of pediatrics at the University of Copenhagen, said, "These data suggest that there is early life eosinophilic activation prior to symptom debut in children developing atopy-related conditions. The mechanism behind the apparent presymptom eosinophilic activation in very young children is still unknown, but this study suggests that there is an ongoing pathogenesis in these children that begins well before symptom onset and includes the activation of eosinophil granulocytes." The study was published online on June 16, 2011 in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

University of Copenhagen




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.